PARP1 and hepatocellular carcinoma: As shown in Figure 5A-C, compared with single-drug treatment group, including Olaparib and DCZ0415, combination group exhibited higher inhibition level in HCC cells, which indicated that DCZ0415 increased Olaparib efficiency in HCC cells, combination with TRIP13 inhibitor DCZ0415 and PARP1 inhibitor Olaparib may be a potential therapy for HCC.